Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2016.07.005 ◽

2016 ◽

Vol 16 (6) ◽

pp. 471-479.e1 ◽

Cited By ~ 13

Author(s):

Denise A. Yardley ◽

James Reeves ◽

E. Claire Dees ◽

Cynthia Osborne ◽

Devchand Paul ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Previously Treated ◽

Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058356 ◽

1993 ◽

Vol 4 (1) ◽

pp. 45-50 ◽

Cited By ~ 35

Author(s):

K. Mross ◽

C. Bohn ◽

L. Edler ◽

W. Jonat ◽

W. Queisser ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Randomized Phase Ii

P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.

10.1158/0008-5472.sabcs11-p5-19-02 ◽

2011 ◽

Author(s):

L Vahdat ◽

P Gopalakrishna ◽

AA Garcia ◽

C Vogel ◽

C Pellegrino ◽

...

Keyword(s):

Breast Cancer ◽

Peripheral Neuropathy ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Eribulin Mesylate ◽

Randomized Phase Ii

Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

10.1158/1538-7445.sabcs17-gs2-07 ◽

2018 ◽

Cited By ~ 9

Author(s):

P Schmid ◽

M Zaiss ◽

C Harper-Wynne ◽

M Ferreira ◽

S Dubey ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Mtor Inhibitor ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Abstract OT2-09-01: A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study)

10.1158/1538-7445.sabcs19-ot2-09-01 ◽

2020 ◽

Author(s):

José Manuel Pérez-García ◽

Alfonso Cortés Salgado ◽

Elena López Miranda ◽

Antonio Antón ◽

Pedro Sánchez Rovira ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Randomized Phase Ii ◽

Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)

10.1158/1538-7445.sabcs18-pd1-10 ◽

2019 ◽

Author(s):

WR Parulekar ◽

AA Joy ◽

K Gelmon ◽

M Mates ◽

C Desbiens ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Second Line ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000722 ◽

2019 ◽

Vol 30 (4) ◽

pp. 394-401

Author(s):

Joachim Bischoff ◽

Jana Barinoff ◽

Christoph Mundhenke ◽

Dirk O. Bauerschlag ◽

Serban-Dan Costa ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Pretreated Patients ◽

Her 2

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

Annals of Oncology ◽

10.1093/annonc/mdx772 ◽

2018 ◽

Vol 29 (3) ◽

pp. 661-668 ◽

Author(s):

A. Gennari ◽

Z. Sun ◽

U. Hasler-Strub ◽

M. Colleoni ◽

M.J. Kennedy ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Maintenance Schedules ◽

First Line Treatment

First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

BMC Cancer ◽

10.1186/1471-2407-5-151 ◽

2005 ◽

Vol 5 (1) ◽

Cited By ~ 15

Author(s):

Djelila Allouache ◽

Sulochana R Gawande ◽

Michele Tubiana-Hulin ◽

Nicole Tubiana-Mathieu ◽

Sophie Piperno-Neumann ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽